Literature DB >> 35858247

Intestinal FFA3 mediates obesogenic effects in mice on a Western diet.

Kristen R Lednovich1, Chioma Nnyamah1, Sophie Gough1, Medha Priyadarshini1, Kai Xu1, Barton Wicksteed1, Sidharth Mishra2, Shalini Jain2, Joseph L Zapater1,3, Hariom Yadav2, Brian T Layden1,3.   

Abstract

Free fatty acid receptor 3 (FFA3) is a recently-deorphanized G-protein-coupled receptor. Its ligands are short-chain fatty acids (SCFAs), which are key nutrients derived from the gut microbiome fermentation process that play diverse roles in the regulation of metabolic homeostasis and glycemic control. FFA3 is highly expressed within the intestine, where its role and its effects on physiology and metabolism are unclear. Previous in vivo studies involving this receptor have relied on global knockout mouse models, making it difficult to isolate intestine-specific roles of FFA3. To overcome this challenge, we generated an intestine-specific knockout mouse model for FFA3, Villin-Cre-FFA3 (Vil-FFA3). Model validation and general metabolic assessment of male mice fed a standard chow diet revealed no major congenital defects. Because dietary changes are known to alter gut microbial composition, and thereby SCFA production, an obesogenic challenge was performed on male Vil-FFA3 mice and their littermate controls to probe for a phenotype on a high-fat, high-sugar "Western diet" (WD) compared with a low-fat control diet (CD). Vil-FFA3 mice versus FFA3fl/fl controls on WD, but not CD, were protected from the development of diet-induced obesity and exhibited significantly less fat mass as well as smaller adipose depositions and adipocytes. Although overall glycemic control was unchanged in the WD-fed Vil-FFA3 group, fasted glucose levels trended lower. Intestinal inflammation was significantly reduced in the WD-fed Vil-FFA3 mice, supporting protection from obesogenic effects. Furthermore, we observed lower levels of gastric inhibitory protein (GIP) in the WD-fed Vil-FFA3 mice, which may contribute to phenotypic changes. Our findings suggest a novel role of intestinal FFA3 in promoting the metabolic consequences of a WD, including the development of obesity and inflammation. Moreover, these data support an intestine-specific role of FFA3 in whole body metabolic homeostasis and in the development of adiposity.NEW & NOTEWORTHY Here, we generated a novel intestine-specific knockout mouse model for FFA3 (Vil-FFA3) and performed a comprehensive metabolic characterization of mice in response to an obesogenic challenge. We found that Vil-FFA3 mice fed with a Western diet were largely protected from obesity, exhibiting significantly lower levels of fat mass, lower intestinal inflammation, and altered expression of intestinal incretin hormones. Results support an important role of intestinal FFA3 in contributing to metabolism and in the development of diet-induced obesity.

Entities:  

Keywords:  FFA3; gut microbiota; metabolic homeostasis; obesity; short-chain fatty acid receptor

Mesh:

Year:  2022        PMID: 35858247      PMCID: PMC9448285          DOI: 10.1152/ajpendo.00016.2022

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   5.900


  66 in total

1.  Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content.

Authors:  Mohamed Bellahcene; Jacqueline F O'Dowd; Ed T Wargent; Mohamed S Zaibi; David C Hislop; Robert A Ngala; David M Smith; Michael A Cawthorne; Claire J Stocker; Jonathan R S Arch
Journal:  Br J Nutr       Date:  2012-10-31       Impact factor: 3.718

2.  Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice.

Authors:  Myung H Kim; Seung G Kang; Jeong H Park; Masashi Yanagisawa; Chang H Kim
Journal:  Gastroenterology       Date:  2013-05-07       Impact factor: 22.682

3.  The incretin system in healthy humans: The role of GIP and GLP-1.

Authors:  Jens Juul Holst
Journal:  Metabolism       Date:  2019-04-25       Impact factor: 8.694

4.  Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases.

Authors:  Serena Sanna; Natalie R van Zuydam; Anubha Mahajan; Alexander Kurilshikov; Arnau Vich Vila; Urmo Võsa; Zlatan Mujagic; Ad A M Masclee; Daisy M A E Jonkers; Marije Oosting; Leo A B Joosten; Mihai G Netea; Lude Franke; Alexandra Zhernakova; Jingyuan Fu; Cisca Wijmenga; Mark I McCarthy
Journal:  Nat Genet       Date:  2019-02-18       Impact factor: 38.330

5.  Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease.

Authors:  Wei Wang; Liping Chen; Rui Zhou; Xiaobing Wang; Lu Song; Sha Huang; Ge Wang; Bing Xia
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

6.  Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment.

Authors:  Ravinder Nagpal; Bryan J Neth; Shaohua Wang; Suzanne Craft; Hariom Yadav
Journal:  EBioMedicine       Date:  2019-08-30       Impact factor: 8.143

Review 7.  Factors Affecting Gut Microbiome in Daily Diet.

Authors:  Qi Su; Qin Liu
Journal:  Front Nutr       Date:  2021-05-10

8.  Short insulin tolerance test can determine the effects of thiazolidinediones treatment in type 2 diabetes.

Authors:  Mi Young Lee; Jang Hyun Koh; Soo Min Nam; Pil Moon Jung; Joong Kyung Sung; Song Yi Kim; Jang Yel Shin; Young Goo Shin; Choon Hee Chung
Journal:  Yonsei Med J       Date:  2008-12-31       Impact factor: 2.759

9.  Unique Gut Microbiome Signatures Depict Diet-Versus Genetically Induced Obesity in Mice.

Authors:  Ravinder Nagpal; Sidharth P Mishra; Hariom Yadav
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

Review 10.  Metabolic and inflammatory functions of short-chain fatty acid receptors.

Authors:  Daniele Bolognini; Domonkos Dedeo; Graeme Milligan
Journal:  Curr Opin Endocr Metab Res       Date:  2020-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.